SCHEMBL3636775

SCHEMBL3636775

Oc1ccc(Cl)c2c1sc1ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.43
ALDH1A1 P00352 6/20 0.41
MAPT P10636 6/20 0.41
KDM4E B2RXH2 5/20 0.41
GAA P10253 4/20 0.41
LMNA P02545 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
HTT P42858 3/20 0.40
JAK2 O60674 1/20 0.40
GPR3 P46089 1/20 0.40
EGLN1 Q9GZT9 1/20 0.39
PTPN1 P18031 1/20 0.39
TNKS O95271 1/20 0.39
TNKS2 Q9H2K2 1/20 0.39
MCL1 Q07820 1/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30422223 1.00 ALOX5 (0.43) ALOX5ALDH1A1MAPTKDM4EGAA
SCHEMBL1615170 0.87 MAOB (0.51) ALOX5ALDH1A1MAPTKDM4EGAA
SCHEMBL3886209 0.79 IDO1 (0.47) ALOX5ALDH1A1MAPTKDM4EGAA
SCHEMBL22311238 0.79 PLK4 (0.43) MAPTKDM4EMEN1KMT2AGPR3
SCHEMBL21862373 0.79 MAPT (0.40) MAPTKDM4EMEN1KMT2AGPR3
SCHEMBL8413396 0.77 MAOA (0.51) ALOX5ALDH1A1MAPTKDM4EGAA
SCHEMBL24343669 0.76 MAPK1 (0.45) ALOX5ALDH1A1MAPTKDM4EGAA
SCHEMBL23168590 0.76 CYP2A6 (0.38) ALOX5MAPTMEN1KMT2AGPR3
SCHEMBL5218956 0.75 MAOA (0.57) ALOX5ALDH1A1MAPTKDM4EGAA
SCHEMBL13311458 0.75 ALDH1A1 (0.41) ALOX5ALDH1A1MAPTKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11851423-B2 Heterocyclic compound and organic light emitting device comprising the same LG CHEM, LTD. (KR) 2023-12-26 US disclosed
US-20200039971-A1 NOVEL HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME LG CHEM, LTD. (KR) 2020-02-06 US disclosed
US-20200039971-A1 NOVEL HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME LG CHEM, LTD. (KR) 2020-02-06 US disclosed
EP-2176254-A1 DNA PK INHIBITORS Kudos Pharmaceuticals Limited (GB) 2010-04-21 EP disclosed
US-20090042865-A1 DNA-PK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-02-12 US disclosed
US-20090042865-A1 DNA-PK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-02-12 US disclosed
US-20090042865-A1 DNA-PK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-02-12 US disclosed
WO-2009010761-A1 DNA PK INHIBITORS KUDOS PHARMACEUTICALS LIMITED (GB) 2009-01-22 WO disclosed
WO-2009010761-A1 DNA PK INHIBITORS KUDOS PHARMACEUTICALS LIMITED (GB) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042865-A1 DNA-PK INHIBITORS DNA2, PKN2, TOP1 ALOX5 4618/4885ALDH1A1 3995/4885MAPT 4759/4885
US-20200039971-A1 NOVEL HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME CRY1, CRY2, CYP1A1 ALOX5 1016/4885ALDH1A1 39/4885MAPT 961/4885
US-11851423-B2 Heterocyclic compound and organic light emitting device comprising the same CRY1, CYP1A1, CRY2 ALOX5 797/4885ALDH1A1 39/4885MAPT 992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.